X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs DIVIS LABORATORIES - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD DIVIS LABORATORIES WYETH LTD/
DIVIS LABORATORIES
 
P/E (TTM) x 27.7 35.3 78.5% View Chart
P/BV x 5.3 6.9 78.0% View Chart
Dividend Yield % 1.3 0.7 194.8%  

Financials

 WYETH LTD   DIVIS LABORATORIES
EQUITY SHARE DATA
    WYETH LTD
Mar-13
DIVIS LABORATORIES
Mar-18
WYETH LTD/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,0441,142 91.5%   
Low Rs818533 153.4%   
Sales per share (Unadj.) Rs298.6146.6 203.7%  
Earnings per share (Unadj.) Rs57.233.0 173.3%  
Cash flow per share (Unadj.) Rs58.438.4 152.1%  
Dividends per share (Unadj.) Rs17.0010.00 170.0%  
Dividend yield (eoy) %1.81.2 152.9%  
Book value per share (Unadj.) Rs249.5222.8 112.0%  
Shares outstanding (eoy) m22.72265.47 8.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.15.7 54.6%   
Avg P/E ratio x16.325.3 64.2%  
P/CF ratio (eoy) x15.921.8 73.1%  
Price / Book Value ratio x3.73.8 99.3%  
Dividend payout %29.730.3 98.1%   
Avg Mkt Cap Rs m21,157222,318 9.5%   
No. of employees `0000.510.8 4.6%   
Total wages/salary Rs m4004,561 8.8%   
Avg. sales/employee Rs Th13,787.43,616.0 381.3%   
Avg. wages/employee Rs Th813.0423.8 191.9%   
Avg. net profit/employee Rs Th2,643.3814.9 324.4%   
INCOME DATA
Net Sales Rs m6,78338,915 17.4%  
Other income Rs m3531,134 31.1%   
Total revenues Rs m7,13640,049 17.8%   
Gross profit Rs m1,61712,617 12.8%  
Depreciation Rs m271,425 1.9%   
Interest Rs m613 41.4%   
Profit before tax Rs m1,93812,313 15.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m6323,543 17.8%   
Profit after tax Rs m1,3018,770 14.8%  
Gross profit margin %23.832.4 73.5%  
Effective tax rate %32.628.8 113.4%   
Net profit margin %19.222.5 85.1%  
BALANCE SHEET DATA
Current assets Rs m6,98445,351 15.4%   
Current liabilities Rs m2,0566,507 31.6%   
Net working cap to sales %72.699.8 72.8%  
Current ratio x3.47.0 48.7%  
Inventory Days Days99127 78.3%  
Debtors Days Days2495 25.2%  
Net fixed assets Rs m24421,160 1.2%   
Share capital Rs m227531 42.8%   
"Free" reserves Rs m5,44158,625 9.3%   
Net worth Rs m5,66859,156 9.6%   
Long term debt Rs m250-   
Total assets Rs m7,90167,832 11.6%  
Interest coverage x353.3926.8 38.1%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.6 149.7%   
Return on assets %16.512.9 127.7%  
Return on equity %22.914.8 154.8%  
Return on capital %34.020.8 163.4%  
Exports to sales %0.20-   
Imports to sales %36.321.8 166.7%   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,4658,485 29.1%   
Fx inflow Rs m1532,359 0.0%   
Fx outflow Rs m2,6779,042 29.6%   
Net fx Rs m-2,66223,317 -11.4%   
CASH FLOW
From Operations Rs m9237,759 11.9%  
From Investments Rs m317-4,783 -6.6%  
From Financial Activity Rs m-481-3,142 15.3%  
Net Cashflow Rs m759-166 -457.3%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 11.8 95.8%  
FIIs % 7.2 19.0 37.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 17.2 176.7%  
Shareholders   21,978 31,796 69.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   STERLING BIOTECH  SANOFI INDIA  ALKEM LABORATORIES  SHASUN PHARMA  PFIZER  

Compare WYETH LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD - LUPIN LTD COMPARISON

COMPARE WYETH LTD WITH

MARKET STATS